Nicola Coley

Summary

Country: France

Publications

  1. doi Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
    Nicola Coley
    University of Toulouse III, France
    Alzheimers Dement 7:602-610.e2. 2011
  2. doi Dementia prevention: methodological explanations for inconsistent results
    Nicola Coley
    INSERM unit 558, Toulouse, France
    Epidemiol Rev 30:35-66. 2008
  3. ncbi How should we deal with missing data in clinical trials involving Alzheimer's disease patients?
    N Coley
    INSERM U558 University of Toulouse III, F 31073, France
    Curr Alzheimer Res 8:421-33. 2011
  4. doi Long-term progression of Alzheimer's disease in patients under antidementia drugs
    Sophie Gillette-Guyonnet
    Department of Internal Medicine and Geriatrics, Purpan University Hospital, Gerontopole Toulouse University Hospital, France
    Alzheimers Dement 7:579-92. 2011
  5. doi Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study
    Virginie Gardette
    Department of Epidemiology and Public Health, Toulouse University Hospital, Université de Toulouse UPS, INSERM U558, Gerontopole, Toulouse, France
    CNS Drugs 24:431-42. 2010
  6. doi Predictive factors of attrition in a cohort of Alzheimer disease patients. The REAL.FR study
    Nicola Coley
    INSERM, U558, University of Toulouse III, Toulouse, France
    Neuroepidemiology 31:69-79. 2008
  7. doi Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit
    Maria E Soto
    Department of Geriatric Medicine, Gérontopôle de Toulouse, Toulouse University Hospital, Toulouse, France
    J Am Med Dir Assoc 13:486.e1-6. 2012
  8. pmc Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study)
    Fati Nourhashemi
    Gerontopole, CMRR, Toulouse, France
    BMJ 340:c2466. 2010
  9. doi Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial
    Bruno Vellas
    INSERM U1027, Toulouse, France
    Lancet Neurol 11:851-9. 2012
  10. doi Cardiovascular disease risk factors and progression of Alzheimer's disease
    Gabor Abellan van Kan
    INSERM U558, Department of Geriatric Medicine, CHU Toulouse, Toulouse, France
    Dement Geriatr Cogn Disord 27:240-6. 2009

Detail Information

Publications14

  1. doi Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
    Nicola Coley
    University of Toulouse III, France
    Alzheimers Dement 7:602-610.e2. 2011
    ..We evaluated the psychometric properties of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) to assess its suitability as a single primary endpoint as an alternative to the traditional co-primary approach...
  2. doi Dementia prevention: methodological explanations for inconsistent results
    Nicola Coley
    INSERM unit 558, Toulouse, France
    Epidemiol Rev 30:35-66. 2008
    ..Because of the multifactorial origin of dementia, it appears that multidomain interventions could be a suitable candidate for preventive interventions, but designing such trials remains very challenging for researchers...
  3. ncbi How should we deal with missing data in clinical trials involving Alzheimer's disease patients?
    N Coley
    INSERM U558 University of Toulouse III, F 31073, France
    Curr Alzheimer Res 8:421-33. 2011
    ..This work highlights the importance of considering the validity of the underlying hypotheses of methods used for handling missing data in AD trials...
  4. doi Long-term progression of Alzheimer's disease in patients under antidementia drugs
    Sophie Gillette-Guyonnet
    Department of Internal Medicine and Geriatrics, Purpan University Hospital, Gerontopole Toulouse University Hospital, France
    Alzheimers Dement 7:579-92. 2011
    ..Data regarding the long-term disease progression outside of therapeutic trials are lacking. We examined the effects of standard of care for AD patients on the prognosis of the disease in a real-life study over a 4-year period...
  5. doi Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study
    Virginie Gardette
    Department of Epidemiology and Public Health, Toulouse University Hospital, Université de Toulouse UPS, INSERM U558, Gerontopole, Toulouse, France
    CNS Drugs 24:431-42. 2010
    ..There is a lack of data concerning the optimal drug treatment duration and the reasons for discontinuation, particularly outside the clinical trial setting...
  6. doi Predictive factors of attrition in a cohort of Alzheimer disease patients. The REAL.FR study
    Nicola Coley
    INSERM, U558, University of Toulouse III, Toulouse, France
    Neuroepidemiology 31:69-79. 2008
    ..Attrition, i.e. patient dropout, can threaten the validity of results in longitudinal studies. The aim of this study was to identify patient and caregiver factors predictive of attrition in a cohort of Alzheimer disease (AD) patients...
  7. doi Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit
    Maria E Soto
    Department of Geriatric Medicine, Gérontopôle de Toulouse, Toulouse University Hospital, Toulouse, France
    J Am Med Dir Assoc 13:486.e1-6. 2012
    ..To describe hospitalizations in a Special Acute Care inpatient Unit for older adults with Alzheimer's disease (AD) and other related disorders...
  8. pmc Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study)
    Fati Nourhashemi
    Gerontopole, CMRR, Toulouse, France
    BMJ 340:c2466. 2010
    ..To test the effectiveness of a comprehensive specific care plan in decreasing the rate of functional decline in patients with mild to moderate Alzheimer's disease compared with usual care in memory clinics...
  9. doi Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial
    Bruno Vellas
    INSERM U1027, Toulouse, France
    Lancet Neurol 11:851-9. 2012
    ..We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer's disease in elderly adults with memory complaints...
  10. doi Cardiovascular disease risk factors and progression of Alzheimer's disease
    Gabor Abellan van Kan
    INSERM U558, Department of Geriatric Medicine, CHU Toulouse, Toulouse, France
    Dement Geriatr Cogn Disord 27:240-6. 2009
    ..To assess if cardiovascular disease risk factors (CVDRF) are predictive factors for poorer evolution of Alzheimer's disease (AD) patients in terms of cognitive decline...
  11. ncbi Disease modifying trials in Alzheimer's disease: perspectives for the future
    Bruno Vellas
    Gerontopole, CHU Toulouse, Department of Geriatric Medicine, Toulouse, France
    J Alzheimers Dis 15:289-301. 2008
    ....
  12. ncbi GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data
    Sandrine Andrieu
    INSERM, U558, F 31073, Toulouse, France
    Curr Alzheimer Res 5:406-15. 2008
    ..5% presented a CDR score of 0.5. This study will enable us to evaluate the efficacy of EGb761 in the prevention of AD, and to assess the usefulness of various baseline characteristics as predictors of conversion to AD in this population...
  13. doi Methodological issues in primary prevention trials for neurodegenerative dementia
    Sandrine Andrieu
    INSERM U558, Toulouse, France
    J Alzheimers Dis 16:235-70. 2009
    ..Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition...
  14. doi Endpoints for trials in Alzheimer's disease: a European task force consensus
    Bruno Vellas
    INSERM U558, Toulouse, France
    Lancet Neurol 7:436-50. 2008
    ..A clear and consensual definition of endpoints is crucial for the success of further clinical trials in the field and will allow comparison of data across studies...